4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (FDMT), a late-stage biotechnology company, has announced its participation in two major healthcare investor conferences in May 2025. The company's management will engage in fireside chats at the BofA Securities 2025 Healthcare Conference on May 14 at 2:20 p.m. PT and the RBC Capital Markets 2025 Global Healthcare Conference on May 21 at 9:00 a.m. ET. Management will also be available for one-on-one meetings with investors. Webcasts of both presentations will be accessible through the company's investor relations website for up to one year.
4D Molecular Therapeutics (FDMT), un'azienda biotecnologica in fase avanzata, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a maggio 2025. Il management dell'azienda prenderà parte a discussioni informali al BofA Securities 2025 Healthcare Conference il 14 maggio alle 14:20 PT e al RBC Capital Markets 2025 Global Healthcare Conference il 21 maggio alle 9:00 ET. Il management sarà inoltre disponibile per incontri individuali con gli investitori. Le trasmissioni web di entrambe le presentazioni saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda per un periodo fino a un anno.
4D Molecular Therapeutics (FDMT), una empresa biotecnológica en etapa avanzada, ha anunciado su participación en dos importantes conferencias para inversores en el sector salud en mayo de 2025. La dirección de la compañía participará en charlas informales en la BofA Securities 2025 Healthcare Conference el 14 de mayo a las 2:20 p.m. PT y en la RBC Capital Markets 2025 Global Healthcare Conference el 21 de mayo a las 9:00 a.m. ET. Además, la dirección estará disponible para reuniones individuales con inversores. Las retransmisiones de ambas presentaciones estarán accesibles a través del sitio web de relaciones con inversores de la compañía durante un año.
4D Molecular Therapeutics (FDMT), 후기 단계의 생명공학 회사가 2025년 5월 두 개의 주요 헬스케어 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 5월 14일 오후 2시 20분(태평양 표준시)에 열리는 BofA Securities 2025 Healthcare Conference와 5월 21일 오전 9시(동부 표준시)에 열리는 RBC Capital Markets 2025 Global Healthcare Conference에서 대담에 참여할 예정입니다. 또한 경영진은 투자자와의 일대일 미팅도 진행할 예정입니다. 두 발표 모두의 웹캐스트는 회사 투자자 관계 웹사이트를 통해 최대 1년간 시청할 수 있습니다.
4D Molecular Therapeutics (FDMT), une entreprise biotechnologique en phase avancée, a annoncé sa participation à deux grandes conférences pour investisseurs dans le secteur de la santé en mai 2025. La direction de la société participera à des discussions informelles lors de la BofA Securities 2025 Healthcare Conference le 14 mai à 14h20 PT et lors de la RBC Capital Markets 2025 Global Healthcare Conference le 21 mai à 9h00 ET. La direction sera également disponible pour des réunions individuelles avec les investisseurs. Les webdiffusions des deux présentations seront accessibles via le site web des relations investisseurs de la société pendant une durée allant jusqu'à un an.
4D Molecular Therapeutics (FDMT), ein Biotechnologieunternehmen in der Spätphase, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Gesundheitswesen im Mai 2025 angekündigt. Das Management des Unternehmens wird am BofA Securities 2025 Healthcare Conference am 14. Mai um 14:20 Uhr PT sowie am RBC Capital Markets 2025 Global Healthcare Conference am 21. Mai um 9:00 Uhr ET in informellen Gesprächen teilnehmen. Das Management steht auch für Einzelgespräche mit Investoren zur Verfügung. Webcasts beider Präsentationen werden über die Investor-Relations-Website des Unternehmens bis zu einem Jahr zugänglich sein.
- None.
- None.
EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in May. Members of the management team will also be available for one-on-one meetings.
BofA Securities 2025 Healthcare Conference
| Presentation Date: | Wednesday, May 14, 2025 |
| Presentation Time: | 2:20 p.m. PT |
| Webcast Link: | Webcast |
RBC Capital Markets 2025 Global Healthcare Conference
| Presentation Date: | Wednesday, May 21, 2025 |
| Presentation Time: | 9:00 a.m. ET |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When is FDMT presenting at the BofA Securities Healthcare Conference 2025?
When is FDMT's presentation at the RBC Capital Markets Healthcare Conference 2025?
Where can I access the webcast of FDMT's investor conference presentations?
Will FDMT management be available for one-on-one meetings at the healthcare conferences?
